Anaptys Top-Line GEMINI-2 Phase 3 Clinical Trial Results Of Imsidolimab In Generalized Pustular Psoriasis; Patients Who Received A Single Dose Of 750mg IV Imsidolimab, 53% Achieved A GPP Physician Global Assessment Score Of 0/1 (Clear Or Almost Clear Skin) At Week 4
Portfolio Pulse from Benzinga Newsdesk
AnaptysBio, Inc. (NASDAQ:ANAB) announced positive results from its GEMINI-1 and GEMINI-2 Phase 3 trials of imsidolimab for treating generalized pustular psoriasis (GPP). In GEMINI-1, 53% of patients receiving a 750mg IV dose achieved clear or almost clear skin at Week 4. In GEMINI-2, patients on monthly maintenance dosing of imsidolimab maintained clear skin with no flares, while those on placebo saw a 63% flare rate. Safety profiles were consistent across trials. AnaptysBio plans to out-license imsidolimab in 2024.
May 09, 2024 | 9:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AnaptysBio's positive Phase 3 trial results for imsidolimab in GPP treatment could significantly impact its stock. The successful trial outcomes and the plan to out-license imsidolimab in 2024 highlight potential future revenue streams and partnerships.
The positive trial results directly relate to AnaptysBio's core business of developing immunology therapeutics. The successful outcomes and the strategic plan to out-license imsidolimab could attract investor interest, potentially leading to a short-term uptick in ANAB's stock price. The announcement of these results and future plans are likely to be viewed positively by the market, given the demand for effective treatments in orphan diseases like GPP.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100